Carmichael Hill & Associates’s Moderna MRNA Stock Holding History

Carmichael Hill & Associates’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Hold	0	–	–	–	469
2024 Q2	–	Hold	0	–	–	–	391
2024 Q1	–	Hold	0	–	–	–	417
2023 Q4	–	Hold	0	–	–	–	480
2023 Q3	–	Hold	0	–	–	–	461
2023 Q2	–	Hold	0	–	–	–	440
2023 Q1	–	Hold	0	–	–	–	488
2022 Q4	–	Hold	0	–	–	–	280
2022 Q3	–	Hold	0	–	–	–	391
2022 Q2	–	Sell	-300	Closed	-$42.9K	–	356
2022 Q1	$52K	Hold	300	–	–	0.02%	351
2021 Q4	$76K	Hold	300	–	–	0.03%	286
2021 Q3	$115K	Hold	300	–	–	0.06%	230
2021 Q2	$70K	Hold	300	–	–	0.04%	293
2021 Q1	$39K	Buy	+300	New	+$43.5K	0.02%	379

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Carmichael Hill & Associates's MRNA Position: Q3 2024 in Review

Carmichael Hill & Associates increased its Moderna (MRNA) stake by 9.6% in Q3 2024, buying an estimated $459 and bringing the position to 57 shares worth $3.81K. The position accounts for ﹤0.01% of the portfolio, ranked #681.

Carmichael Hill & Associates first reported a position in MRNA in Q2 2020 and has held it in 18 quarters since. The position peaked at $46K in Q3 2021. 790 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

Carmichael Hill & Associates held 57 shares of Moderna worth $3.81K as of Q3 2024.
Carmichael Hill & Associates bought 5 Moderna shares in Q3 2024, an estimated $459.
Moderna made up ﹤0.01% of Carmichael Hill & Associates's portfolio in Q3 2024, its #681 holding.
Carmichael Hill & Associates first reported a position in Moderna in Q2 2020 and has held it in 18 quarters since.
Carmichael Hill & Associates's Moderna position peaked at $46K in Q3 2021.
790 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Carmichael Hill & Associates's 13F filing for Q3 2024, filed 29 Oct 2024.